70,154 Shares in The Oncology Institute, Inc. (NASDAQ:TOI) Bought by WealthShield Partners LLC

Key Points

• WealthShield Partners LLC has acquired 70,154 shares in The Oncology Institute, Inc. (NASDAQ:TOI), valued at approximately $80,000, representing about 0.09% of the company's stock.
• In recent trading, Oncology Institute's shares have shown a performance increase of 2.2%, with a current price of $4.16 and a market capitalization of $371.21 million.
• Several analysts have given positive ratings for the stock, including a new "outperform" rating from Noble Financial with a target price of $8.00.

WealthShield Partners LLC acquired a new stake in shares of The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 70,154 shares of the company's stock, valued at approximately $80,000. WealthShield Partners LLC owned 0.09% of Oncology Institute at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of TOI. Jane Street Group LLC grew its holdings in shares of Oncology Institute by 613.6% during the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock worth $39,000 after purchasing an additional 109,769 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Oncology Institute by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after acquiring an additional 12,000 shares during the period. Finally, XTX Topco Ltd boosted its holdings in Oncology Institute by 49.5% during the first quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock worth $63,000 after buying an additional 18,448 shares during the last quarter. 36.86% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on TOI. B. Riley initiated coverage on Oncology Institute in a report on Wednesday, July 16th. They set a "buy" rating and a $6.00 price objective for the company. Noble Financial began coverage on shares of Oncology Institute in a report on Wednesday, July 23rd. They set an "outperform" rating and a $8.00 target price for the company. Finally, BTIG Research began coverage on Oncology Institute in a research note on Thursday, May 15th. They issued a "buy" rating and a $7.00 price target for the company.

Oncology Institute Stock Performance

NASDAQ:TOI traded down $0.02 on Tuesday, reaching $4.22. 515,805 shares of the company's stock were exchanged, compared to its average volume of 1,437,540. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.79 and a quick ratio of 1.59. The firm has a market cap of $376.55 million, a price-to-earnings ratio of -6.02 and a beta of 0.08. The Oncology Institute, Inc. has a 52 week low of $0.13 and a 52 week high of $4.50. The stock has a fifty day simple moving average of $3.02 and a 200-day simple moving average of $2.15.

Oncology Institute (NASDAQ:TOI - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. The company had revenue of $104.41 million for the quarter. Oncology Institute had a negative net margin of 15.38% and a negative return on equity of 445.02%.

Insider Activity at Oncology Institute

In other news, Director Growth I. L.P. M33 sold 1,796,468 shares of Oncology Institute stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $2.71, for a total value of $4,868,428.28. Following the sale, the director directly owned 14,624,233 shares in the company, valued at approximately $39,631,671.43. This trade represents a 10.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brad Hively sold 1,976,137 shares of Oncology Institute stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $2.87, for a total value of $5,671,513.19. Following the completion of the sale, the director owned 603,501 shares in the company, valued at approximately $1,732,047.87. This represents a 76.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,726,137 shares of company stock worth $13,379,013. 8.50% of the stock is owned by corporate insiders.

Oncology Institute Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.